<DOC>
	<DOCNO>NCT01954784</DOCNO>
	<brief_summary>This phase I trial study side effect best dose lenalidomide donor stem cell transplant bortezomib treat patient high-risk multiple myeloma . Giving low dos chemotherapy total-body irradiation donor stem cell transplant help stop growth cancer cell . It may also patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving bortezomib time transplant may stop happen . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Giving lenalidomide donor stem cell transplant may effective treatment multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide After Donor Stem Cell Transplant Bortezomib Treating Patients With High Risk Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Identify maximal tolerate dose ( MTD ) safety lenalidomide 10mg follow non-myeloablative allogeneic stem cell transplant multiple myeloma . SECONDARY OBJECTIVES : I. Assess safety tolerability weekly bortezomib follow non-myeloablative allogeneic stem cell transplant . II . Obtain estimate non-relapse mortality . III . Obtain estimate acute chronic graft-versus-host disease ( GVHD ) . IV . Obtain estimate 1 year relapse survival . OUTLINE : This dose-escalation study lenalidomide . PREPARATIVE REGIMEN : Patients receive fludarabine phosphate day -5 -3 undergo total body irradiation ( TBI ) day -1 . TRANSPLANT : Patients undergo allogeneic hematopoietic stem cell transplant ( SCT ) day 0 . GVHD PROPHYLAXIS : Patients receive standard GVHD prophylaxis comprise cyclosporine orally ( PO ) twice daily ( BID ) begin day -1 taper begin day 100 , mycophenolate mofetil PO BID day 1-56 , bortezomib subcutaneously ( SC ) weekly day 1 day 91 . MAINTENANCE THERAPY : Beginning day 100 , patient receive lenalidomide PO daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 1 year post-transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Symptomatic multiple myeloma International Myeloma Working Group ( IMWG ) criterion accord recent updated version ( International Myeloma Workshop [ IMW ] meeting Paris 2011 ) Must receive least 3 follow class antimyeloma agent either alone combination : glucocorticoid , immunomodulatory drug include thalidomide , proteasome inhibitor , alkylating chemotherapy , anthracyclines Must meet criterion high risk disease : Relapse progressive disease accord uniform response criterion within 2 year start firstline therapy within 2 year autologous stem cell transplant Failure achieve partial response ( PR ) within 6 month star firstline therapy Presence high risk cytogenetic feature ( ( 14 ; 16 ) , ( 14 ; 20 ) , deletion 17p ) Chromosome 14 translocation chromosome 11 Chromosome 1p deletion 1q amplification MyPRS gene expression score equal high 45.2 High risk 70 gene expression profile ( MyPRS GEP70TM ) Any high risk genetic profile determine future IMWG consensus internal myeloma panel consensus ; latter , additional criterion submit addendum Diagnosis multiple myeloma age 1850 Must achieve least minor response previous regimen accord adapted European Group Blood Marrow Transplantation ( EBMT ) criterion Must suitable matched sibling match unrelated donor stem cell source Must transplanteligible per institution guideline Must estimate glomerular filtration rate ( eGFR ) Modification Diet Renal Disease ( MDRD ) formula CockroftGault formula 50mL/min high All study participant must register mandatory Revlimid REMS® program , willing able comply requirement Revlimid REMS® Females childbearing potential must negative serum urine pregnancy test use acceptable birth control methods Able take aspirin daily prophylactic anticoagulation ( patient intolerant acetylsalicylic acid [ ASA ] may use warfarin low molecular weight heparin ) Participants must : Have know hypersensitivity thalidomide lenalidomide Have progressive disease time transplant Uncontrolled concurrent significant medical psychological comorbidity Grade 3 peripheral neuropathy Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) ; patient seropositive hepatitis B virus vaccine eligible Be female pregnant Recent ( within 3 year ) history malignancy , exclude basal cell carcinoma squamous cell carcinoma skin Be currently enrol another investigational treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>